Conference Coverage

Exclusive Preview: Bioelectronic Medicine for Treatment of Rheumatoid Arthritis

07/02/2020

In this exclusive video preview of an on-demand session from Interdisciplinary Autoimmune Summit (IAS) 2020, David Chernoff, MD, introduces the concept of neuroimmune control of inflammation and its implications for treating patients with rheumatoid arthritis.

Dr Chernoff is the chief medical officer of SetPoint Medical.

Register to learn more from Dr Chernoff's full presentation. IAS will be held from July 10 through July 12, 2020. Visit iasmeeting.com to learn more.

Popular Articles

Q&As

Alan Bonder, MD, on Extrahepatic Autoimmune Diseases in Patients With Primary Biliary Cholangitis

10/21/2020

About 25% of patients with one autoimmune disease are likely to develop another autoimmune condition. Dr Bonder, from Beth Israel Deaconess Medical Center in Boston, talks about the importance of screening patients with primary biliary...

About 25% of patients with one...

10/21/2020

Gastroenterology

News

Still Disease, Anxiety, and Depression: What’s the Connection?

12/25/2020

The researchers investigated mood status and health-related quality of life among patients with adult-onset Still disease. Here is what they found.

The researchers investigated...

12/25/2020

Autoimmune

News

Smoking and Psoriasis Risk: What Is the Connection?

10/30/2020

Researchers examined the impact of cigarette smoking on the prevalence and incidence of psoriasis and psoriatic arthritis. Here is what they found.

Researchers examined the impact...

10/30/2020

Autoimmune

Pop Quiz

Pop Quiz: Ankylosing Spondylitis and IBD

09/16/2020

Do you know whether ankylosing spondylitis affects patients with Crohn disease more often than those with ulcerative colitis, or vice versa? Find out by taking our pop quiz!

Do you know whether ankylosing...

09/16/2020

Autoimmune

News

TNF-α Inhibitor Antibodies Negatively Affect Course of Inflammatory Joint Disease

07/31/2020

The presence of drug-induced neutralizing antibodies against tumor necrosis factor-α inhibitors may be a reliable biomarker for assessing treatment efficacy in patients with inflammatory joint diseases, a recent study shows.

The presence of drug-induced...

07/31/2020

Autoimmune

Stay In the Know

Autoimmune Newsletter

Exclusive Preview: Bioelectronic Medicine for Treatment of Rheumatoid Arthritis

Popular Articles

Stay In the Know

Specialties

Events

Year Round Education

HMP Global Products